← Companies|Sprint Bio
Sp

Sprint Bio

Huddinge SEFounded 201430 employees
Private CapbiotechPrivateOncology
Platform: SBP-101
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
SPR-5098SPR-5098Phase 22Cell TherapyCD20IL-13iPV
SPR-7869SPR-7869Phase 11ASOIL-17AHER2PTSD
CapiosocimabSPR-1942Phase 1/22NanobodySMN2SOS1iIPF
DaranesiranSPR-7863Preclinical2RadioligandIL-17ACAR-T CD19CholangiocarcinomaEoE
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)
2026-01-18
Capiosocimab Conference
IPF
Past
2028-04-25
Daranesiran Interim
Cholangiocarcinoma
Interim
2028-07-10
Daranesiran Interim
Cholangiocarcinoma
Interim
2028-07-19
Capiosocimab Ph2 Data
IPF
Ph2 Data
2031-06-05
Capiosocimab Ph2 Data
IPF
Ph2 Data